CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, will hold a webcast on December 29, 2022 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss the performance of leronlimab in its clinical trials and the recent charges against its former CEO Nader Pourhassan, who was previously terminated on January 24, 2022, and has had no affiliation with the Company since that time.

Webcast Access Information

Date: Thursday, December 29, 2022
Time: 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time
Access: https://event.choruscall.com/mediaframe/webcast.html?webcastid=i2RX9JZG

The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until January 29, 2023.

About CytoDyn
CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions.

CONTACTS
Investors:
Cristina De Leon
Office: 360.980.8524
ir@cytodyn.com

Media:
Greg Salsburg
STiR Communications
info@stir-communications.com

Staff

Recent Posts

Fangzhou Launches Otsuka’s Third-Generation Leukemia Drug Ponatinib on its Platform

GUANGZHOU, China, May 5, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in…

3 hours ago

SprintRay Appoints Dr. Meena Barsoum as Global Head of Clinical Strategy

LOS ANGELES, May 5, 2025 /PRNewswire/ -- SprintRay, the global leader in dental 3D printing,…

3 hours ago

FendX Announces Share Issuance Pursuant to IP License Agreement

Oakville, Ontario--(Newsfile Corp. - May 5, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…

7 hours ago

The Lens Magazine Features Joe Kiani, Willow Laboratories Founder and Nutu Visionary, on Cover of Latest Issue Following LSI USA ‘25 Keynote

DANA POINT, Calif.--(BUSINESS WIRE)--The Lens, LSI’s executive-focused medtech magazine, proudly unveils Volume 2, Edition 3,…

9 hours ago

eMed Announces Collaboration with Aon to Provide a Digital GLP-1 Benefit Program for Aon colleagues

Partnership provides virtual clinical support with data driven measurement to improve adherence for obesity management MIAMI, May 5, 2025 /PRNewswire/ -- eMed®,…

9 hours ago